20.760 articles found

Visual mismatch negativity in Parkinson's psychosis and potential for testing treatment mechanisms.

Vignando M, Ffytche D, Mazibuko N, Palma G, Montagnese M, Dave S, Nutt DJ, Gabay AS, Tai YF, Batzu L, Leta V, Williams Gray CH, Chaudhuri KR, Mehta MA.

Brain Commun · 2024-09-03

DOI: 10.1093/braincomms/fcae291PMID: 39355002

Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies.

Dai L, Liu M, Ke W, Chen L, Fang X, Zhang Z.

Cell Mol Life Sci · 2024-09-03

DOI: 10.1007/s00018-024-05419-5PMID: 39223418

Therapeutic drug monitoring in Parkinson's disease.

Müller T, Gerlach M, Hefner G, Hiemke C, Jost WH, Riederer P.

J Neural Transm (Vienna) · 2024-09-03

DOI: 10.1007/s00702-024-02828-5PMID: 39227478

DJ-1: Potential target for treatment of myocardial ischemia-reperfusion injury.

Ji YW, Wen XY, Tang HP, Jin ZS, Su WT, Zhou L, Xia ZY, Xia ZY, Lei SQ.

Biomed Pharmacother · 2024-09-03

DOI: 10.1016/j.biopha.2024.117383PMID: 39232383

Nanotherapeutic Approaches of Interleukin-3 to Clear the α-Synuclein Pathology in Mouse Models of Parkinson's Disease.

Zhang W, Ren J, Ding L, Zheng S, Ma R, Zhang M, Liu Y, Liang R, Zhang Y.

Adv Sci (Weinh) · 2024-09-03

DOI: 10.1002/advs.202405364PMID: 39225429

Jaw-opening dystonia in Parkinson's disease improved by foslevodopa-foscarbidopa continuous subcutaneous infusion: a case report.

Okumura M, Mukai Y, Tanimura J, Takahashi Y.

Neurol Sci · 2024-09-03

DOI: 10.1007/s10072-024-07740-0PMID: 39223422

Treatment of Neuropsychiatric Symptoms in Parkinson's Disease With Botulinum Toxin A: A 12 week Randomized, Double-Blind, Placebo-Controlled Trial.

Zhu X, Wei M, Wang L, Tong Q, Yang X, Han Q.

J Geriatr Psychiatry Neurol · 2024-09-03

DOI: 10.1177/08919887241281066PMID: 39226071

Effects of subthalamic nucleus deep brain stimulation on the speech of Spanish-speaking Parkinson's disease patients during the first year of treatment.

Castillo-Triana N, Camargo-Mendoza M, Bernal-Pacheco Ó.

Codas · 2024-09-02

DOI: 10.1590/2317-1782/20242023194enPMID: 39230179

Targeting the Labile Iron Pool with Engineered DFO Nanosheets to Inhibit Ferroptosis for Parkinson's Disease Therapy.

Lei L, Yuan J, Dai Z, Xiang S, Tu Q, Cui X, Zhai S, Chen X, He Z, Fang B, Xu Z, Yu H, Tang L, Zhang C.

Adv Mater · 2024-09-02

DOI: 10.1002/adma.202409329PMID: 39221531

Target modulation of glycolytic pathways as a new strategy for the treatment of neuroinflammatory diseases.

Wang H, Liu S, Sun Y, Chen C, Hu Z, Li Q, Long J, Yan Q, Liang J, Lin Y, Yang S, Lin M, Liu X, Wang H, Yu J, Yi F, Tan Y, Yang Y, Chen N, Ai Q.

Ageing Res Rev · 2024-09-02

DOI: 10.1016/j.arr.2024.102472PMID: 39233146

Transition Metal Complexes as Therapeutics: A New Frontier in Combatting Neurodegenerative Disorders through Protein Aggregation Modulation.

Navale GR, Ahmed I, Lim MH, Ghosh K.

Adv Healthc Mater · 2024-09-02

DOI: 10.1002/adhm.202401991PMID: 39221545

Therapeutic potential of Canna edulis RS3-resistant starch in alleviating neuroinflammation and apoptosis in a Parkinson's disease rat model

He QK, Wang XY, Huwei, Cai J, Chen P, Liu M, Wu YH.

Heliyon · 2024-09-01